Selpercatinib for RET-Altered Thyroid Cancer and MTC: Lori Wirth, MD

In this interview, Lori Wirth, MD, speaks with i3 Health about selpercatinib (RetevmoTM, Eli Lilly), which was recently approved by the FDA for the treatment of patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), advanced/metastatic RET-mutant medullary thyroid cancer (MTC), and advanced/metastatic RET fusion-positive thyroid cancer. Dr. Wirth, Medical Director of the Center for Head and Neck Cancers at Massachusetts General Hospital and first author of the phase 1/2...
Continue reading

Exciting Treatment Advances in Upper Tract Urothelial Cancer: Seth P. Lerner, MD, FACS

Substantial developments are under way in the treatment of upper tract urothelial cancer (UTUC). Seth P. Lerner, MD, FACS, recently spoke with i3 Health about mitomycin gel (JelmytoTM, UroGen Pharma), now FDA approved as the first agent specifically indicated for the treatment of low-grade UTUC. In this second installment of his interview, Dr. Lerner, principal investigator of the OLYMPUS study, on which the mitomycin gel approval was based, discusses research advances in the treatment of both l...
Continue reading

Tucatinib for HER2-Positive Metastatic Breast Cancer: Eric P. Winer, MD

In this interview with i3 Health, Eric P. Winer, MD, discusses tucatinib (TukysaTM, Seattle Genetics), recently approved by the FDA in combination with trastuzumab and capecitabine for patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer previously treated with at least one anti-HER2­–based regimen in the metastatic setting. Dr. Winer, principal investigator of the phase 3 HER2CLIMB trial, on which the approval was based, discusses tucat...
Continue reading

​COVID-19 and Cancer: Addressing Patients' Concerns With Mark A. Lewis, MD

Patients with cancer often have concerns related to the COVID-19 pandemic, from which they are potentially at increased danger as a result of their cancer and/or due to immunosuppressive treatments. Mark A. Lewis, MD, Director of Gastrointestinal Oncology at Intermountain Healthcare, Murray, Utah, recently published a perspective piece in The New England Journal of Medicine contemplating the challenges of balancing the necessity of cancer care against the risks of COVID-19. A couple of week...
Continue reading

Family History-Based Colorectal Cancer Screening: Samir Gupta, MD

Colorectal cancer rates in younger adults are currently rising, and those with a family history of the disease face an even greater risk. Samir Gupta, MD, Chief of the Gastrointestinal (GI) Section of the San Diego Veterans Affairs Healthcare System, recently spoke with i3 Health about his research team's finding, now published in Cancer, that only 25% of patients between the ages of 40 to 49 who were diagnosed with colorectal cancer as a result of screening met the family history-based early sc...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.